{
    "clinical_study": {
        "@rank": "9912", 
        "arm_group": [
            {
                "arm_group_label": "Part A", 
                "arm_group_type": "Experimental", 
                "description": "A single dose of 2 fixed-dose combination tablets of 200mg lumacaftor/125mg ivacaftor (total of 400mg lumacaftor/250mg ivacaftor) in the fed state and fasted state with a 14 day washout period in between each dosing occasion"
            }, 
            {
                "arm_group_label": "Part B", 
                "arm_group_type": "Experimental", 
                "description": "A single dose of 3 fixed-dose combination tablets of 200mg lumacaftor/83mg ivacaftor (total of 600mg lumacaftor and 250mg ivacaftor) in the fed with a 14 day washout period in between dosing occasions"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to investigate the effect of food on the relative bioavailability of\n      2 different strengths of fixed-dose combinations of lumacaftor and ivacaftor tablet\n      formulations."
        }, 
        "brief_title": "A Phase 1 Study to Investigate the Food Effect of Lumacaftor in Combination With Ivacaftor", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Cystic Fibrosis", 
        "condition_browse": {
            "mesh_term": [
                "Cystic Fibrosis", 
                "Fibrosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male and female subjects as defined in the protocol\n\n          -  Subjects who weigh >50 kg at Screening\n\n        Exclusion Criteria:\n\n          -  History of any illness or condition that might confound the results of the study or\n             pose an additional risk to the subject upon administration of study drug   - Positive\n             for hepatitis B,C, or HIV\n\n          -  Standard 12-lead ECG demonstrating QTc >450 msec for male subjects and >480 msec for\n             female subjects at the Screening Visit\n\n          -  Abnormal renal function as defined in the protocol at Screening\n\n          -  Forced expiratory volume in 1 second (FEV1) <80% predicted at the Screening Visit\n\n          -  Blood donation (of approximately 1 pint [500 mL] or more) within 56 days before the\n             first dose of study drug\n\n          -  Treatment with an investigational drug or device within 30 days or 5 half-lives\n             preceding the first dose of study drug"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01899105", 
            "org_study_id": "VX13-809-012"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Part A", 
                    "Part B"
                ], 
                "intervention_name": "lumacaftor", 
                "intervention_type": "Drug", 
                "other_name": "VX-809"
            }, 
            {
                "arm_group_label": [
                    "Part A", 
                    "Part B"
                ], 
                "intervention_name": "ivacaftor", 
                "intervention_type": "Drug", 
                "other_name": "VX-770"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 2, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Daytona", 
                    "country": "United States", 
                    "state": "Florida"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Randomized, Single-Dose, Open-Label Crossover Study to Investigate the Effect of Food on the Relative Bioavailability of 2 Fixed-Dose Combinations of Lumacaftor and Ivacaftor Tablet Formulations in Healthy Adult Subjects", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Pharmacokinetic parameters of lumacaftor and ivacaftor, including Cmax, AUC0-tlast, and AUC0-\u221e", 
            "safety_issue": "No", 
            "time_frame": "up to 5 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01899105"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Safety and tolerability as assessed by adverse events (AEs), laboratory assessments (serum chemistry and hematology), vital signs, standard 12-lead electrocardiograms (ECGs), and spirometry", 
            "safety_issue": "Yes", 
            "time_frame": "up to 25 days"
        }, 
        "source": "Vertex Pharmaceuticals Incorporated", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Vertex Pharmaceuticals Incorporated", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}